The Claim
Testosterone therapy initiated without documented hypogonadism is associated with a 23% higher risk of ischemic stroke over a 10-year period compared to testosterone therapy initiated with documented hypogonadism, with a hazard ratio of 1.23 (95% CI 1.14–1.33), indicating a specific association with cerebrovascular events.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People who start testosterone therapy without a diagnosed low testosterone level have a 23% higher chance of having an ischemic stroke within 10 years compared to those who start therapy after a documented diagnosis of hypogonadism.
See the scientific wording
Testosterone therapy initiated without documented hypogonadism is associated with a 23% higher risk of ischemic stroke over 10 years compared to therapy initiated with documented hypogonadism, with a hazard ratio of 1.23 (95% CI 1.14–1.33), suggesting a specific link to cerebrovascular events.
Testosterone increases the number of red blood cells, making the blood thicker and slower-moving. This thick blood sticks to artery walls, especially in small brain vessels, and forms clots that block blood flow to the brain, causing a stroke.
What the research says
1 studyStudy: Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men
Men who started testosterone therapy without being diagnosed as having low testosterone had a 23% higher chance of having a stroke over 10 years compared to men who started it after a confirmed diagnosis. This suggests the therapy may be riskier when used without a clear medical reason.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.